Subject Index

A

ACTH-secreting tumors
  V_3R antagonists and treatment of, 190, 196
Activating transcription factor-1 (ATF-1), 487–88
Adenosine, 775–84
  inflammation and, 475–84
  ischemia and, 775–84
  metabolism, 777–78
  tissue protection and, 775, 780–81
Adenosine receptors, 775–84
  characteristics, 776–77
  mast cells and, 775, 781–82
  pharmacology, 782–84
  preconditioning and, 775
Adenylyl cyclases (ACs), 146–62
  alcohol abuse and, 155–57
  brain function and, 147–50
  brown adipose tissue and, 153
  calcium-inhibitable, 150–52
  cell differentiation and, 152–53
  cyclic AMP synthesis and, 145
  drug dependency and, 154–55
  genetic diseases and, 157
  genetic mice, 157–58
  isoforms, 145–62
  pharmacology of, 158–59
    adenosine derivatives and, 159
    forskolin and, 158
  spermatozoa and, 153–54
  tissue distribution, 146–48
ADP-ribosyl cyclase, 317–35
  structure and mechanisms, 318–20
Ah receptor, 297–303
  cytochrome P450 CYP1B1 expression and, 297–303
    human, 300–1
    rodent, 302–3
    tumor, 297, 299
A-kinase anchoring proteins (AKAPs), 763–64, 766
Alcohol abuse
  cyclic AMP signaling pathway and, 155–57
Alzheimer's disease
  drug treatment effects on, 625–26, 630–31, 637–39, 642–43
  estrogen's protective effects against, 570, 578, 582
  glycogen synthase kinase-3 and, 802–3
  pharmacogenetics and, 108
β-Aminobutyric acid
  See GABA
γ-Amyloid peptides
  formation and toxicity
    estrogen's protective effects against, 582–83
Anesthetics (general)
  gaseous, 27, 32, 42–43
  ligand-gated ion channels and
    molecular modeling of interactions with, 34–40
    recombinant, 25–27
  minimum alveolar concentration, 25
  molecular mechanisms of, 23–43
  molecular sites of action, 32–34
Angiogenesis
  antiangiogenic activity of vitamin D, 421, 423, 433–35
Anticancer chemotherapy
  comparative genomic hybridization and, 110–11
  See also Cancer chemoprevention
Anticancer drugs
  cytochrome P450 CYP1B1 and, 299, 306, 309, 311
  topoisomerase I-targeting, 53–64
    camptochecin and, 54–61, 63–64
    mechanisms of topisomerase I inhibition, 55–56
  topoisomerease II-targeting, 53, 64–68
    daunorubicin, 64
    doxorubicin, 64
    mechanisms of inhibition, 64–66
    mitoxantrone, 64
    SUMO and, 53, 63
    ubiquitin and, 53, 61–62
Antidepressant
  neurokinin$_1$ receptor antagonists as, 877–96
  substance P and, 877–96
    effects of antidepressant drugs on, 887
    monoamine-substance P interactions, 881–83
    stress and, 885–86

Antidiuretic
aquaretics and, 175, 186–90, 195
arginine vasopressin (AVP), 175–96
Antioxidants
inhibition of peroxynitrite-mediated oxidation and nitration reactions, 223–34
thioredoxin, 269–70
Antipsychotics, 237–57
adrenergic receptor blocking properties, 244–46
potential psychotogenic pathways and sites of action, 246
psychotogenesis and
hyperdopaminergic model of, 238, 242–44, 249–52
hypoglutaminergic model of, 238, 242–45, 249–52
monoamine-glutamate-GABA interactions and, 237–57
Antisense oligonucleotides, 403–14
bcl-2, 403, 411–14
phosphodiester, 403–14
phosphorothiate, 403–14
RNase H and, 403–4, 408–10
Antitumor drugs
topoisomerase I-targeting, 53, 55–64
camptothecin, 54–61, 63–64
topoisomerase II-targeting, 53, 64–68
daunorubicin, 64
doxorubicin, 64
mitoxantrone, 64
mechanisms of inhibition, 64–66
SUMO and, 53, 63
ubiquitin and, 53, 61–62
Apoptosis
camptothecin-induced, 57–59
DNA damage and, 367, 386–89
p53 and, 388–89
receptor-mediated, 388
thioredoxin and, 273–75
topoisomerase II cleavage complexes and, 67–68
vitamin D's proapoptotic activities, 421, 423, 433–35
Apoptosis signal-regulating kinase 1 (ASK1), 273–75
Aquaretics, 175, 186–90, 195
nonpeptide V_2-renal arginine vasopressin receptor antagonists and, 175, 186–90, 195
L-Arginine, 79–91
biochemistry of, 79–81
cardiovascular effects, 79, 83–88
endothelial function and, 79, 81–91
mechanisms of action, 79, 81, 85–88
nitric oxide synthase substrate provision and, 79, 81, 85–88
nitric oxide and, 79–83
as precursor for, 81–83
paradox, 91
pharmacokinetics, 79, 89–91
side effects, 88–89
vasodilation and, 79, 81, 83–88
Arginine vasopressin (AVP), 175–96
Arginine vasopressin/oxytocin (AVP/OT) receptors
molecular biology of, 175, 179–82, 191–92
Arginin vasopressin (AVP) receptor agonists
nonpeptide, 175–76, 182–90, 192–96
strategies in designing, 182
therapeutic uses
ACTH-secreting tumors, 190
aquaretics, 175, 186–90, 195
arterial hypertension, 175–76
cerebral edema, 188–89
congenital nephrogenic diabetes insipidus, 189
congestive heart failure, 186, 188, 195–96
dysmenorrhea, 175–76, 195,
hypernatremia, 175, 186, 195
liver cirrhosis, 175, 186–88
nephrotic syndrome, 175
syndrome of inappropriate secretion of antidiuretic hormone (SIADH), 175–76, 186
Arginine vasopressin (AVP) receptor subtypes
V_1-vascular (V_1R), 175–78, 182–85, 189–90
V_2-renal (V_2R), 175–76, 186–90
V_3-pituitary (V_3R), 175–76, 178–79, 190
Arnt-Schultz law, 16
Arterial hypertension
nonpeptide vasopressin receptor agonists and treatment of, 175–76
Asthma
adenosine receptors and, 775, 781–82

Asymmetric dimethylarginine (ADMA), 86
Atherosclerosis
endothelial function and L-arginine and, 79, 82–85
tyrosine nitration and, 212
Autocoids
prostaglandins, 661–81
See also Prostaglandins

B

Basal vascular tone
endothelin and, 851, 856–58
Bcl-2
antisense oligonucleotides, 403, 411–14
Bioethics
pharmacogenetics and, 115–16
Bioinformatics, 103, 115
Biomarkers, 347–63
defined, 348
in drug development, 347–63
drug discovery and preclinical development, 347–63
early clinical development, 351–52
late clinical development, 352–53
evaluation of, 353–56
as indicators of drug exposure, 347
pharmacokinetic-pharmacodynamic studies, 351
surrogate endpoints, 347–58
validation as, 356–58
unanticipated adverse consequence of drug therapy and, 349–50
Bipolar disorder
lithium treatment for, 789–91, 803
Bone remodeling
stress-induced osteopontin and, 723, 733–36
Botulinum toxin
pharmacological modulation of lower urinary tract function and, 709–10
Brain function
adenylyl cyclases and, 147–50
Breast cancer
osteopontin expression and, 737
Brown adipose tissue
adenylyl cyclases and, 153

C

CAAT-enhancer binding protein (c/EBP), 487–88
Calabrese, 16
Calcium/calmodulin-dependent protein kinases
See Calcium signaling, Calmodulin kinases
Calcium messengers, 317
multiple, 317
Calcium signaling
in blood cells, 330–31
calmodulin (CaM) and, 471–93
calmodulin kinases and, 471–93
CaM KI, 477–93
CaM KII, 482–93
CaM KIV, 479–93
CaM KK, 480–82
in cardiac and smooth muscle cells, 330–31
homeostasis and, 471–72
inositol trisphosphate (IP_3) and, 317–18, 334–35
intercellular, 333–34
in lymphatic cells, 330–31
nicotinic acid adenine dinucleotide phosphate (NAADP) mediated, 318–35
pharmacology of, 320–22
nitric oxide and mediation of, 325–26
in oocytes, 327–28
in pancreatic acinar cells, 328–29
transcription regulation, 484–93
activating transcription factor-1 (ATF-1) and, 487–88
CAAT-enhancer binding protein (c/EBP) and, 487–88
cAMP-responsive binding element (CREB) and, 484–86, 492
2/histone deacetylase and, 489–91
myocyte enhancer factor-2 (MEF2) and, 489–91
serum response factor (SRF) and, 487–89
Calcium stores, 317, 334–35
Calmodulin (CaM), 471–93
Calmodulin kinases, 471–93
calcium signaling and, 471–93
CaM KI, 477–93
CaM KII, 482–93
CaM KIV, 479–93
CaM KK, 480–82
domain structure, 473–77
transcription regulation, 484–93
activating transcription factor-1 (ATF-1) and, 487–88
CAAT-enhancer binding protein (c/EBP) and, 487–88

cAMP-responsive binding element (CREB) and, 484–86, 492
2/histone deacetylase and, 489–91
myocyte enhancer factor-2 (MEF2) and, 489–91
serum response factor (SRF) and, 487–89
cAMP
See Cyclic AMP
Camptothecin, 53–61, 63–64
apoptotic cell death and, 57–59
cytotoxicity
replication collision model for, 58
topoisomerase I and, 53–61, 63–64
Cancer
breast
osteopontin expression and, 737
colon, 424–26
proapoptotic activities of vitmin D, 424–26
colorectal, 424–25
prostate, 425
skin, 426
Cancer chemoprevention
vitamin D and synthetic analogs for, 421–35
antiangiogenic activity of, 421, 423, 433–35
antiproliferative activity of, 421, 423, 433–35
cheek pouch carcinogenesis and, 426
colon cancer and, 425–26
colorectal cancer and, 424–25
gastrointestinal carcinogenesis and, 426
proapoptotic activity of, 421, 423, 433–35
prodifferentiating activity of, 421, 423, 433–35
prostate cancer and, 425
skin carcinogenesis and, 425–26
sun exposure and cancer rates and, 423–25
See also Anticancer chemotherapy
Cancer drugs
resistance to thioredoxin and, 276
Cancer research
cytochrome P450 CYP1B1 and, 299, 306, 309, 311
as early marker for tumorigenesis, 309, 311
Capsaicin
phramacological modulation of lower urinary tract function and, 708–9
Carcinogenesis
DNA cleavage and, 53–68
cheek pouch, 426
gastrointestinal, 426
skin, 426
See also DNA cleavage; Tumorigenesis
Carcinogens
cytochrome P450 CYP1B1 metabolism and, 297, 299, 303–4
Cardiac hypertrophy
endothelin and, 851, 858–60
Cardiovascular disease
L-arginine's beneficial effects
chronic oral administration, 79, 85
intermittent infusion therapy, 79, 84–85
vasodilation and, 79, 81–88
nitric oxide and, 81–88
Catalase, 216
CD38, 317–20
structure and mechanisms, 318–20
Cell cycle checkpoints
activation in response to DNA damage, 379–83, 389
checkpoint Rad pathway, 379
p53 and, 384–86
Cell survival
osteopontin stimulation of, 723, 728
Cellular immunity
osteopontin and, 723, 730–31
Central cardiorespiratory regulation
endothelin and, 851, 858–62
Cerebral edema
nonpeptide V_2-renal arginine vasopressin receptor antagonists as treatment of, 188–89
Chicago Toxicology Laboratory, 2–5
Clinical endpoints
defined, 348
intermediate endpoint, 348
surrogate endpoints, 347–50, 356–63
biomarkers and, 347–63
defined, 348
ultimate outcome and, 348
Clonidine, 245
Clozapine, 252, 256
Colon cancer
proapoptotic activities of vitamin D, 424–26
Comparative genomic hybridization, 110–11
Computational biology, 3

Congenital nephrogenic diabetes insipidus
nonpeptide V_2-renal arginine vasopressin receptor antagonists and treatment of, 189
Congestive heart failure
dual V_1R/V_2R antagonists and treatment of, 186, 188, 195–96
Constitutive active receptor (CAR)
genes regulated by, 136
nuclear activation of, 133–34
nuclear translocation of, 132–33
phenobarbital and, 123, 131–38
Cyclic ADP-ribose (cADPR), 317–35
agonistic and antagonistic analogs of, 321
calcium signaling and, 317–35
elevated levels after cell activation, 324–25
nitric oxide signaling pathways and, 325
ryanoldine receptor modulation and, 322–23
Cyclic AMP (cAMP)
adenylyl cyclases and, 145–46, 152, 155–62
cell differentiation and, 152–53
compartmentation of cAMP action in heart, 751–67
β-adrenergic receptor subtypes, 756–58
caveolae, 759–63
functional compartments of signaling, 753–56
protein kinase A and A-kinase anchoring proteins, 763–64, 766
protein kinase C and, 764–66
pathway
alcohol abuse and, 155–57
drug dependency and, 154–55
Cyclic AMP-response binding element (CREB)
transcription regulation and, 484–86, 492
Cytochrome P450, 123–38
enzymes, 535–59
drug interactions and, 535–59
genetic polymorphism and, 539–41, 547–59
induction of, 535–36, 542–43, 553–59
inhibition of, 535–36, 542–43, 547–53
variability in content of, 539–41
genes
CYP1B1, 297–311
CYP2B, 124–28
CYP2H, 130
CYP3A, 128–30
CYP6, 131
CYP102/CYP106, 130–31
gene transcription
nuclear receptors and, 123–38
induction
phenobarbital and, 123–38
xenochemical metabolism and, 124
Cytochrome P450 CYP1B1, 297–311
expression
human, 300–1
murine cells and tissues, 310
rodent, 302–3, 310–11
tumor, 297, 299, 306, 309
in human fetal tissues, 308–9
metabolic probes, 305
murine metabolism of, 304–5
normal expression in liver, 306–8
rat metabolism of, 305
regulation, 300–3
Ah receptor and, 300–3
cAMP receptor and, 302–3
structure of human gene, 298

D

Daunorubicin, 64
Defluorination, 458–60
Deltanoids
chemopreventive activity of, 428–35
antiangiogenic, 421, 423, 433–35
antiproliferative, 421, 423, 433–35
proapoptotic, 421, 423, 433–35
prodifferentiating, 421, 423, 433–35
hybrid, 421, 428–35
noncalcemic, 421, 428–35
Depression
role of substance P and neurokinin$_1$ receptors, 888–96
Deslurane, 455
Dexamethasone/rifampicin response element, 128–29
Diabetic nephropathy
drug treatment effects on, 647
Diffuse large B-cell lymphoma, 111
1α,25-Dihydroxyvitamin D_3

analogs, 421, 429–35
Disease progression
definition, 625–26
description methods
ANOVA/ANCOVA, 632
change from baseline, 633
linear and nonlinear, 626, 633
survival analysis, 632
drug modifications of, 627–51
Alzheimer's disease, 625–26, 630–31, 637–39, 642–43
diabetic nephropathy, 647
osteoporosis, 648–50
Parkinson's disease, 625–26, 629–31, 633–37, 643–45
respiratory disease, 645–47
time course effects, 629–30
models
asymptotic, 626–27
linear, 626, 633
Disease status
measuring, 630–32
DNA
nitric oxide modifications of, 219–22
DNA cleavage
camptothecin and camptothecin cytotoxicity and, 57–59
mechanisms of topoisomerase I inhibition by, 55–57
topoisomerase I-mediated, 55–64
topoisomerase II-mediated, 64–68
tumor cell death and, 53–68
See also Carcinogenesis; Tumorigenesis
DNA damage, 367–89
apoptosis and, 367, 386–89
p53 and, 388–89
receptor-mediated, 388
cell cycle checkpoints and, 367, 379–83, 389
checkpoint Rad pathway, 379–84
p53 and, 384–86
DNA repair mechanisms, 367–79, 389
base excision repair (BER) pathway, 367–75
DNA double-strand break repair, 375–79
DNA glycolases and, 367–75
formation of covalent adducts with DNA, 367
hydrolytic deamination of cytosine and 5 methylcytosine bases, 367
hydrolytic depurination, 367
nonhomologous end-joining, 378–79
single-strand annealing, 378
Dopamine
amphetamine-induced release of, 242
schizophrenia and, 237–57
dopamine hypothesis of, 237–39, 252, 254
Dopaminergic stabilizers
schizophrenia and, 240–41
Doxorubicon, 64
Drug development, 347–63
biomarkers and, 347–63
confounding factors, 349
drug discovery and preclinical development, 351
early clinical development, 351–52
late clinical development, 352–53
surrogate endpoints and, 347–63
regulatory review, 347, 350–51, 358–63
Drug interactions, 535–59
cytochrome P450 enzymes and
inhibition and induction of, 535–36, 542–43, 547–59
intestinal first-pass metabolism and, 538–41
liver and, 536–39
quantitative prediction of, 535
Drug metabolism
cytochrome P450 CYP1B1 and, 297–311
anticancer drugs and, 299, 306, 309, 311
cytochrome P450 enzymes and, 535–59
inhibition of, 535
fluorine-containing drugs and, 443–64
drug disposition and, 447
drug distribution and, 447–48
drug metabolism rate, 448–52
prevention of metabolic bioactivation, 452–58
pharmacogenomic influences on, 101–16
polymorphic, 104–7
Drug metabolizing enzymes
ethnic differences in, 815–26
CYP2C subfamily, 816–20
CYP206, 820–23
CYP3A4, 823–26
Drug receptors
ethnic differences in drug

disposition and response, 815, 827–30
α-adrenergic receptor, 827–28
β-adrenergic receptor, 828–30
Drug response
fluorine substitution and, 443
interpatient variability in, 101, 103–4
molecular basis for ethnic differences in, 815–33
drug metabolizing enzymes and, 815–26
drug receptors and, 815, 827–30
drug transporters and, 815, 826–27
nitric oxide synthase and, 830–31
pertussis toxin–sensitive G_i protein, 831–32
pharmacogenetics and, 101–16
polymorphic drug metabolism and, 104–7
polymorphic drug targets and, 107–9
Drug toxicity, 443
Drug transporters
ethnic differences in drug disposition and response, 815, 826–27
p-glycoprotein, 826–27
Drug treatment effects, 625–51
Alzheimer's disease, 625–26, 630–31, 637–39, 642–43
diabetic nephropathy, 647
osteoporosis, 648–50
Parkinson's disease, 625–26, 629–31, 633–37, 643–45
protective, 625, 627–30
respiratory disease, 645–47
symptomatic, 625, 627–29
Dysmenorrhea
nonpeptide V_1-vascular arginine vasopressin receptor agonists and treatment of, 175–76, 185, 195
oxytocin and, 185

E

Embryogenesis, 54
Endothelin pathway, 852–53
Endothelin system, 851–67
components
in brain, 851, 863–65
in development, 855–56
in heart, 851, 858–60
in kidney, 851, 862–63
in lung, 851, 861–62
in vessels, 851, 856–58
Enflurane, 455–56
Enzyme inhibition and induction
drug interactions and, 535–36, 542–43, 547–59
Estradiol, 569–73, 575–84
antioxidant effects, 572, 575–76
neuroprotective effects, 569, 578–84
neurotrophic effects, 569, 576–78
17a, 569–73, 575–84
17β, 569–73, 575–84
Estrogen
antioxidant effects, 572, 575–76, 579–82
carcinogenicity
oxidative metabolism and, 454
mechanism of action, 572–76
neuroprotective effects, 569, 576–78
antiapoptotic effects, 579
astroglial cells and aromatase and, 583
glutamate excitotoxicity and, 582
NMDA excitotoxicity and, 582
neurotrophic effects, 569, 576–78
second messenger cascade, 569, 572–75, 584
sites of estrogen action in brain, 570–72
Estrogen receptors, 569–85
crosstalk with neurotrophins, 574–75, 583–84
ERα, 569–85
ERβ, 569–85
membrane-associated, 569, 574–75
role in estrogen's neuroprotective effects, 583–84
selective estrogen receptor modulators (SERMs) and, 583–84
limitations of, 583–84
Estrogen replacement therapy, 578–84
benefits
Alzheimer's disease, 570, 578, 582
antiapoptotic effects, 579
antioxidant effects, 572, 575–76, 579–82
astroglial cells and aromatase and, 583
cardiovascular disease, 579
mental performance and function, 578
neuroprotection against glutamate excitotoxicity, 582
neuroprotection against NMDA excitotoxicity, 582

osteoporosis, 579
selective estrogen receptor modulators (SERMs), 583–84
limitations of, 583–84
Estrogen response element (ERE), 572–73, 576, 583–84
Ethnicity
drug disposition and response and, 815–33
drug metabolizing enzymes and, 815–26
drug receptors and, 815, 827–30
drug transporters and, 815, 826–27
nitric oxide synthase and, 830–31
pertussis toxin–sensitive G_i protein and, 831–32
N-Ethylamaleimide, 65
Etoposide, 64

F

Ferritin, 217
Fluorine-containing drugs, 443–64
as antimetabolites, 460–63
drug disposition and, 447
drug metabolism rate and, 448–52
metabolic bioactivation prevention of, 452–58
metabolic defluorination, 458–60
physicochemical properties, 444
Fluorouracil, 460–62
Forskolin (FSK)
adenylyl cyclase and, 146–47, 149, 151, 154, 158
Free radicals
nitric oxide, 203–24

G

GABA
monoamine-glutamate-GABA interactions, 237–57
schizophrenia and, 237, 241, 243, 245–47
$GABA_A$ receptor
general anesthesia and, 23–43
Gastrointestinal carcinogenesis
proapoptotic activities of vitamin D and, 426
Gene expression
downregulation of antisense oligonucleotides and, 403–14
Gene regulation
cytochrome P450, 123–38
constitutive active receptor (CAR) and, 123, 131–38
phenobarbital response elements and, 123–38
Genetic polymorphisms
cytochrome P450 enzyme, 539–41, 547–59
induction, 553–59
inhibition, 547–53
ethnic differences in drug disposition and response, 815–33
Genome instability
See DNA damage
Glutamate
monoamine-glutamate-GABA interactions, 237–57
glutamate monoamine interactions at presynaptic level, 244–45
glutamatergic control of monoamine release, 241–44
schizophrenia and, 237–38
Glycogen synthase kinase-3 (GSK-3β), 797–803
Alzheimer's disease and, 802–3
lithium action and, 797–803
G protein-coupled receptor gene family
lysophospholipid receptors, 507–11
G protein-coupled receptors
arginine vasopressin receptor subtypes
V_1-vascular (V_1R), 175–78, 182–85, 189–90
V_2-renal (V_2R), 175–76, 178, 186–96
V_3-pituitary (V_3R), 175–76, 178–79, 190
classification, 594–95
polymorphisms
C-terminal domain, 606–8
extracellular loop domain, 605–6
genetic variations and, 593–615
intracellular loop domain, 603–5
noncoding-region, 608–12
single nucleotide polymorphisms (SNPs), 593–615
transmembrane domain, 599–603
prostaglandins and, 661–81
truncated receptors, 612–13
variations at loci, 595–96
G protein-coupled signaling pathways
compartmentation in cardiac myocytes, 751–67
β-adrenergic receptor

subtypes, 756–58
cAMP action, 751–56
caveolae, 759–63
protein kinase A and A-kinase anchoring proteins, 763–64, 766
protein kinase C and, 764–66
GRAS (generally recognized as safe)
origin of concept, 13

H

Haloperidol, 249–52, 254–56, 448
Halothane, 455–57
hepatotoxicity, 456–57
Hippocrates, 1
2/Histone deacytylase, 489–91
History of toxicology, 1–20
Arnt-Schultz law, 16
Calabrese, 16
certification, 8–10
Chicago Toxicology Laboratory, 2–5
GRAS (generally recognized as safe), 13
Hippocrates, 1
hormesis, 16
journals, 5–6
molecular biology, 16
Orfila, 1
Paracelsus, 1, 16
Society of Toxicology, 7–8
textbooks, 6–7
threshold limit value (TLV), 13–15
transgenic toxicology, 16
US Army Chemical Warfare Service, 2
Hormesis, 16
Human Genome Project
pharmacogenetics and, 102
Hypercholesterolemia
endothelial function and L-arginine and, 79, 82–85
Hyperdopaminergia model of schizophrenia, 238, 240–41, 249–52
Hypoglutamatergia model of schizophrenia, 238, 242–45, 249–52
Hyponatremia
treatment of
aquaretics and, 175, 195
nonpeptide vasopressin receptor antagonists and, 175, 186, 195

I

Immunity
cell-mediated
osteopontin and, 723, 730–31
Induction
cytochrome P450
3-methylcholanthrene and, 123–24
phenobarbital (PB), 123
phenobarbital response elements and, 123–38
Inflammation
adensine receptors and, 775–84
osteopontin and, 728–31
cell-mediated immunity, 723, 730–31
macrophage phagocytosis, 729–30
monocyte/macrophage differentiation, 729
monocyte/macrophage migration, 728–29
Informatics, 103, 115
Inositol monophosphatase
lithium action and, 789, 794–96
Inositol trisphosphate (IP_3), 317–18, 334–35
calcium signaling and, 317–18, 334–35
In silico biology, 103
Intestinal first-pass metabolism
drug interactions and cytochrome P450 enzymes and, 538–39
Iron regulatory protein (IRP), 216–17
Iron response element (IRE), 216–17
Ischemia-reperfusion injury
adenosine receptors and, 775–84
tyrosine nitration and, 212
Isoflurane, 455

K

Kidney
toxicant injury of
osteopontin and, 732–33

L

Leber's congenital amaurosis, 157
Ligand-gated ion channels
anesthetics' molecular action on, 23–32
$GABA_A$ receptors and, 23–43
molecular modeling of, 34–40
nitrous oxide, 27, 32, 42–43
xenon, 27, 32, 42–43
Lipids
nitric oxide and modifications of, 222–23
Lithium
developmental effects, 791
hematopoiesis, 791–92
metabolic effects, 791
molecular targets
glycogen synthase kinase-3, 797–803
inositol monophosphatase, 789, 794–96

phosphomonoesterase, 794–97
Wnt signaling and, 789, 798–802
neuropsychiatric effects, 789–91, 803
bipolar disorder and, 789–91, 803
Liver
cytochrome P450 CYP1B1 expression in, 306–8
cytochrome P450 enzymes in
metabolic drug interactions and, 536–39
Liver cirrhosis
nonpeptide vasopressin receptor agonists and treatment of, 186–88
Long-term depression (LTD)
nitric oxide/cyclic ADP-ribose signaling pathway and, 325–26
Long-term memory (LTM)
adenylyl cyclases and, 148–50
Long-term potentiation (LTP)
adenylyl cyclases and, 148–50
Lower urinary tract, 691–710
anatomy and innervation, 691–92
pharmacological modulation of function
afferent neuropeptides and, 702–4
botulinum toxin and, 710
capsaicin and, 708–9
cholinergic, 693–95
dopaminergic, 698–99
GABAergic inhibitory mechanisms, 702
glutamatergic excitatory mechanisms, 700–1
glycinergic inhibitory mechanisms, 702
neurotrophic factors and, 708
nitric oxide and, 704–5
opioid peptides and, 702
prostanoids and, 705–6
purinergic, 695–98
resiniferatoxin (RTX) and, 709–10
serotonergic, 698–99
voltage-gated ion channels and, 706–8
voiding
dysfunction, 692–93
neural control of, 692
Lysophosphatidic acid (LPA)
See Lysophospholipid receptors; Lysophospholipids
Lysophospholipid receptors, 507–27
G protein-coupled receptor gene family and, 507–11
lysophospholipidic acid receptors, 511–16
sphingosine 1-phosphate receptors, 521–24
sphingosylphosphoryl-choline receptor, 524
Lysophospholipids, 507–27
lysophosphatidic acid (LPA), 507–24, 527
nervous system function, 517–19
production and degradation of extracellular, 520–21
tumor cells and, 519–20
sphingosine 1-phosphate (S1P), 507–11, 524–27
cardiovascular system functions, 524–26
production and function of extracellular, 526–27
tumor cells and, 526
sphingosylphosphoryl-choline (SPC), 524–27
cardiovascular system functions, 524–26
production and function of extracellular, 526–27
tumor cells and, 526

M

m-AMSA, 64
Mast cells, 775, 781–82
Metabolism, drug
See Drug metabolism
Metastasis, 723
Methoxyflurane, 454–56
Minimum alveolar concentration, 25
Mitoxanthrone, 64
MK-801, 242–45, 249–56
Molecular modeling
anesthetics' molecular action on ligand-gated ion channels, 34–40
Monoamines
glutamate-monoamine interactions at postsynaptic level, 244–45
glutamatergic control of release of, 241–44
monoamine-glutamate-GABA interactions, 237–57
schizophrenia and, 237
Movement disorders, 237
Myocardial inflammation
tyrosine nitration and, 212
Myocyte enhancer factor-2 (MEF2), 489–91

N

Nephrotic syndrome
nonpeptide vasopressin receptor and treatment of, 175
N-ethylamaleimide, 65
Neurokinin$_1$ receptor

antagonists, 877–96
MK-869, 877, 893–95
preclinical evaluation, 888–92
substance P and, 877–96
antidepressant activity, 877–96
monoamine-substance P interactions, 881–83
transgenic animals, 886–87
Neurotrophic facotors
pharmacological modulation of lower urinary tract function and, 708
Nicotinic acid adenine dinucleotide phosphate (NAADP), 317–35
active anlogs of, 322
calcium signaling and, 317–35
in oocytes, 327–28
in pancreatic acinar cells, 328–29
Nitric oxide (NO)
L-arginine and, 79–88
autooxidation of, 205–6
calcium signaling mediated by, 325–26
chemistry of, 204–6
cyclic ADP-ribose pathway and, 325
DNA modifications from, 219–22
effect on heme proteins, 214–16
inflammatory disease pathology and, 204
interactions with guanylate cyclase, 203
lipid modifications from, 222–23
nitration and, 203, 205, 209–14
nitrosation and, 205
S-nitrosylation and, 203, 206–9
oxidation and, 205
p53 and, 218
pharmacological modulation of lower urinary tract function and, 704–5
prostaglandin H synthase and, 219
protein radicals and, 218–19
reactions with metal complexes, 204
ribonucleotide reductases and, 219
vascular physiology and pathophysiology and, 81
vasodilation and, 81, 83–88
zinc-finger-containing nuclear receptors and, 218
Nitric oxide synase (NOS)
L-arginine and, 79–88
endothelial
ethnic differences in drug disposition and response and, 830–31
isoforms, 203–4
Nitration
manganese superoxide dismutase, 213
nitric oxide and, 203, 205, 209–14
tyrosine, 209–14
atherosclerotic plaques and, 212
ischemia-reperfusion injury and, 212
myocardial inflammation and, 212
renal hypertension and, 212
Nitrosation, 205
Nitrosylation
nitric oxide and, 203, 206–9
Nitrotyrosine, 209–14
Nitrous oxide
effects on ligand-gated ion channels, 27, 32, 42–43
NMDA, 569, 576, 579, 582
excitotoxicity
estrogen's neuroprotective effects against, 582
oxidative stress and, 579, 582
Nonpeptide arginine vasopressin (AVP) receptor antagonists, 175–76, 182–90, 192–96
See also Arginine vasopressin receptor antagonists
Noradrenaline
schizophrenia and, 237–38, 241, 256–57

O

Opioid peptides
pharmacological modulation of lower urinary tract function and, 702
Orfila, 1
Organophosphate insecticides, 3
Osteopontin (OPN), 723–41
bone remodeling and, 733–36
cellular signaling and, 723–28
inflammatory functions of, 728–31
cell-mediated immunity, 723, 730–31
macrophage phagocytosis, 729–30
monocyte/macrophage migration, 728–29
receptors, 724–28
CD44v, 725–26
integrins, 724–26
toxicant injury and, 723, 732–33
kidney and, 732–33

tumorigenesis and, 736–40
vasculature and, 731–32
Osteoporosis
drug treatment effects on, 625, 648–50
Oxidant injury
thioredoxin and protection against, 269–71
Oxidative damage
estrogen's protective effect against, 569, 572, 575–76, 579–82
NMDA and, 569, 576, 579, 582
Oxytocin, 176, 185
Oxytocin receptor, 175–76, 179, 191–92

P

p53
nitric oxide crosstalk with, 218
thioredoxin and binding of, 272–73
p54
DNA damage and repair and
apoptosis and, 388–89
cell cycle checkpoints and, 384–86
Paracelsus, 1, 16
Parkinson's disease
drug treatment effects, 625–26, 629–31, 643–45
angiotensin-converting enzyme (ACE), 629
selegilene and tocopherol, 629
estrogen's protective effect against, 570, 578, 582
Peroxisome proliferator activated receptor α, 137
Peroxynitrite, 206
Pertussis toxin–sensitive G_i protein, 831–32
Pharmacogenetics, 101–16
current technology, 102–3
drug development and, 113–14
drug metabolism and, 104–7
ethics and, 115–16
gene expression and, 111–13
high-density, 110–11
comparative genomic hybridization (CGH), 110–11
polymorphism
drug metabolism, 104–7
drug targets, 107–9
single nucleotide polymorphism (SNP), 108–10, 113–14
population, 815–33
thiopurine methyltransferase and (TPMT), 104–7, 113–14
Phenobarbital (PB)
mechanism of induction, 131–35
constitutive active receptor (CAR) and, 123, 131–35
phenobarbital-responsive enhancer molecule (PBREM) and, 123, 126–27, 131
pregnane X receptor (PXR) and, 123, 129–32
xenobiotic responsive module and, 123, 128–29
Phenobarbital (PB) response elements, 123–38
cytochrome P450 and genes, 123–38
induction of, 123–38
xenobiotic responsive module (XREM), 123, 128–31
Phenobarbital-responsive enhancer molecule (PBREM), 123, 126, 131, 137
Phosphomonophosphatase
lithium action and, 789, 794–97
Phosphorothioate oligodeoxynucleotides, 403–14
Polymorphisms
pharmacogenetics and
polymorphic drug metabolism, 104–7
polymorphic drug targets, 107–9
single nucleotide polymorphism (SNP), 108–10, 113–14
Preconditioning
adenosine receptors and, 775–81
Pregnane X receptor (PXR), 123, 129–32, 134–35
activation of, 134–35
phenobarbital induction and, 131–32, 134–35
Pregnane X receptor response element, 130
Prostaglandin H synthase
interaction with nitric oxide, 219
Prostaglandins, 661–81
Prostanoid receptors, 661–81
DP receptors, 680–81
FP receptor, 670–71
IP receptors, 679–80
multiple E-prostanoid receptors, 671–79
TxA_2 (TP) receptor, 668–70
Prostate cancer
proapoptotic activities of vitamin D and, 425
Protein binding
thioredoxin and, 273–75
Protein folding
thioredoxin and, 277
Protein kinase A
compartmentation of G protein-coupled signaling

pathways and, 751–67
Protein radicals
nitric oxide reactions with, 218
Prozazine, 244
Psychogenesis
hyperdopaminergia model of, 238, 240–41, 249–52
hypoglutamatergia model of, 238, 242–45, 249–52
monoamine-glutamate-GABA interactions and, 237–57

Q

Quinolone, 448

R

Raloxifene, 583
Raltitrexed, 110
Raynaud's phenomenon
nitric oxide deficiency and, 85
Reactive nitrogen species (RNS), 203–4, 218
tumor suppressor p53 and, 218
Reactive oxygen species (ROS)
DNA glycolase and, 370–73
Recombinant receptors
anesthetic actions on, 23–27
Regulatory review
biomarkers and, 347, 350–51, 358–63
investigational new drugs, 351
legal basis, 358
new drug applications, 350
Renal hypertension
tyrosine nitration and, 212
Renal salt handling
endothelin and, 851, 862–63
Reperfusion injury
protection against thioredoxin and, 276–77
Resiniferatoxin (RTX)
pharmacological modulation of lower urinary tract function and, 709–10
Respiratory disease
drug treatment effects on, 645–47
Retinoid X receptor (RXR), 126–27
Ribonucleotide reductases
nitric oxide interactions with, 219
RNase H, 403–4, 408–10
irrelevant cleavage and, 408–10
Ryanodine receptor (RyR), 320–35
cyclic ADP-ribose modulation, 322–23

S

Schizophrenia, 237–57
dopamine and, 237–57
dopamine hypothesis of, 237–39, 252, 254
hyperdopaminergic model of, 238, 240–41, 249–52
hypoglutaminergic model of, 238, 242–45, 249–52
monoamine-glutamate-GABA interactions and, 237–57
noradrenaline and, 237–38, 241, 256–57
serotonin and, 237–38, 241–42, 246, 251, 254, 256–57
5′UTR polymorphism, 609–10
Second messengers
estrogen and G protein-linked, 569, 572–75, 584
Selective estrogen receptor modulators (SERMs), 583–84
limitations of, 583–84
Selective serotonin uptake inhibitors, 448
Selenium
effects on thioredoxin peroxidase, 271
Serotonin
schizophrenia and, 237–38, 241–42, 246, 251, 254, 256–57
Serum response factor (SRF), 487–89
Sevoflurane, 455
Signal transduction
adenylyl cyclases and, 145–62
cAMP signaling pathway and, 147, 155–62
LTM and, 149
LTP and, 148–50
arginine vasopressin (AVP) receptor subtypes and, 177–79
oxytocin receptor and, 179
Simvastatin, 352–53
Single nucleotide polymorphisms (SNPs), 108–10, 113–14, 593–615
G protein-coupled receptors and, 593–615
Skin cancer
vitamin D and chemoprevention of, 423–26
Society of Toxicology, 7–8
Sphingosine 1-phosphate (S1P), 507–11, 524–27
cardiovascular system functions, 524–26
production and function of extracellular, 526–27
tumor cells and, 526

Sphinosylphosphorylcholine (SPC), 524–27
cardiovascular system functions, 524–26
production and function of extracellular, 526–27
tumor cells and, 526
Stabilizers
See Dopaminergic stabilizers
Substance P
antidepressant activity of, 877–96
monoamine-substance P interactions, 881–83
depression and, 892–96
substance P systems
effects of antidepressant drugs on, 887
stress and, 885–86
SUMO, 53, 63
Superoxide radicals, 203
Surrogate endpoints, 347–63
biomarkers and, 347–63
as confirmatory evidence, 359
validation of biomarkers as, 356–58
Syndrome of inappropriate secretion of antidiuretic hormone (SIADH), 175–76, 186

T

Tamoxifen, 583
Thioguanine, 104–5
Thiopurine methyltransferase (TPMT), 104–7, 113–14
deficiency in drug response and, 105–7
pharmacogenetics and, 104–7, 113–14
Thioredoxins (Trx), 261–82
Alzheimer's disease and, 279
as antioxidant, 269–71
apoptosis inhibition and, 273, 275
atherosclerosis and, 278
cancer and, 279–81
cancer drug resistance and, 276
cioned forms, 262–63
as cofactor, 270
drugs that inhibit, 280–81
as growth factor, 268–69
HIV and, 279
immune function and, 278–79
interferon-gamma growth arrest and, 277
mutant forms, 262
peroxidase, 271
in plasma, 278
processed forms, 264
protein binding and, 273–75
protein folding and, 277
redox biochemistry, 262
reductase, 261–62
regulation of expression, 267
reperfusion injury protection and, 276–77
selenium's effect on, 271
skin damage and, 278
structure, 264–67
subcellular localization, 268
transcription factor regulation and, 270–73
transgenic mice, 277
Threshold limit value
origin of concept, 13–15
Thromboxane, 668–70
Topoisomerase, 53–68
anticancer drugs and, 54–68
topoisomerase I-targeting, 53, 64–68
topoisomerase II-targeting, 63, 64–68
DNA damage and, 55–68
topoisomerase I-mediated, 55–64
topoisomerase II-mediated, 64–68
tumor cell death and, 63–68
Transcription
calcium signaling cascades, 471–93
calmodulin kinases and, 471–93
regulation, 484–93
activating transcription factor-1 (ATF-1) and, 487–88
CAAT-enhancer binding protein (c/EBP) and, 487–88
cAMP-responsive binding element (CREB) and, 484–86, 492
2/histone deacetylase and, 489–91
myocyte enhancer factor-2 (MEF2) and, 489–91
serum response factor (SRF) and, 487–89
Transcription factor regulation
thioredoxin and, 270–73
Tucaresol, 352
Tumor cell death, 53–68
anticancer drugs and, 54–68
topoisomerase I-targeting, 53, 64–68
topoisomerase II-targeting, 63, 64–68
topoisomerase-mediated DNA cleavage and, 53, 55–64
Tumor cells
cytochrome P450 CYP1B1 expression in, 297, 299, 306, 309, 311

as early-stage tumor marker, 309, 311
lysophosphatidic acid (LPA) and, 519–20
sphingosine 1-phosphate and, 526
sphingosylphosphorylcholine and, 524
Tumorigenesis
osteopontin and, 736–40
thioredoxin and, 270–71
See also Carcinogenesis; DNA damage

U

Ubiquitin
topoisomerase I downregulation and, 61–62
Urea cycle
L-arginine and, 80
US Army Chemical Warfare Service, 2

V

Vasopressin receptors and antagonists
See Arginine vasopressin receptors; Arginine vasopressin antagonists
Vitamin D
chemopreventive activity of, 421–35
antiangiogenic, 421, 423, 433–35
antiproliferative, 421, 423, 433–35
proapoptotic, 421, 423, 433–35
prodifferentiating, 421, 423, 433–35
dose-limiting toxicity, 427–28
altered calcium metabolism, 427–28
preclinical evidence of chemopreventive efficiency, 425–28
cheek pouch carcinogenesis, 426
colon cancer, 425–26
gastrointestinal carcinogenesis, 426
skin carcinogenesis, 426
xenograft models, 427–28
sun exposure and cancer rates, 423–25
colorectal cancer, 424–25
prostate cancer, 425

W

Wnt signaling
lithium and, 789, 798–802

X

Xenobiotic-response elements
CYP1B1 gene expression and, 300
Xenobiotic responsive module (XREM), 123, 128–31, 137
CYP3A gene induction and, 128–29
Xenochemical metabolism
cytochrome P450 and, 124
Xenochemical response elements, 123
Xenon
effects on ligand-gated ion channels, 27, 32, 42–43

Z

Zafirlukast, 351–52
Zinc-finger-containing nuclear receptors
effect of nitric oxide on, 21

CUMULATIVE INDEXES

CONTRIBUTING AUTHORS, VOLUMES 37–41

Acosta D Jr, 38:63–96
Allen JW, 39:151–73
Amara SG, 39:431–56
Ambudkar SV, 39:361–97
Anders MW, 38:501–37
Anderson SP, 40:491–518
Aposhian HV, 37:397–419
Aschner M, 39:151–73
Atkinson AJ Jr, 41:347–66

Bagdassarian CK, 41:661–90
Baker RC, 39:127–50
Bakhle YS, 38:97–120
Balboa MA, 39:175–89
Balsinde J, 39:175–89
Benovic JL, 38:289–319
Bertaccini E, 41:23–51
Blackburn TP, 40:319–34
Blaschke TF, 37:451–75
Blau HM, 40:295–317
Bode-Böger SM, 41:79–99
Böger RH, 41:79–99
Borges K, 39:221–41
Borjigin J, 39:53–65
Botting RM, 38:97–120
Bradfield CA, 40:519–61
Branchek TA, 40:319–34
Brett CM, 38:431–60
Breyer MD, 41:661–90
Breyer RM, 41:661–90
Briggs JM, 37:71–90
Broder S, 40:97–132
Brown JH, 40:459–89
Brunton LL, 41:751–73
Burgen ASV, 40:1–16
Burke MD, 41:297–316

Carlsson A, 41:237–60
Carlsson ML, 41:237–60
Catterall WA, 37:361–96
Chan PLS, 41:625–59
Changeux J-P, 40:431–58
Chaudhuri G, 37:477–515
Choudhuri S, 39:267–94
Chun J, 41:507–34
Clapham DE, 37:167–203
Coles P, 41:175–202
Collins MD, 39:399–430
Conn PJ, 37:205–37
Contos JJA, 41:507–34
Corringer P-J, 40:431–58
Corton JC, 40:491–518
Costa E, 38:321–50
Costa LG, 38:21–43

Dalton TP, 39:67–101
Davila JC, 38:63–96
Davis KL, 41:203–36
Debouck C, 40:193–208
Defer N, 41:145–74
de Groat WC, 41:691–721
Dekant W, 38:501–37
Denhardt DT, 41:723–49
Dennis EA, 39:175–89
De Vries L, 40:235–71
Dey S, 39:361–97
Dingledine R, 39:221–41
Doull J, 41:1–21
Dunham EW, 37:53–69

Elenko E, 40:235–71
Elliott JD, 40:177–91
Evans WE, 41:101–21

Farquhar MG, 40:235–71
Felder CC, 38:179–200
Fischer T, 40:235–71
Fisher JW, 38:1–20
Flexner C, 40:651–76
Fu H, 40:619–49
Fukushima N, 41:507–34

Giachelli CM, 41:723–49
Giacomini KM, 38:431–60
Gibbs JB, 37:143–66
Gillette JR, 40:19–41
Glass M, 38:179–200
Goldstein A, 37:1–28
Gottesman MM, 39:361–97
Greenlee WF, 41:297–316
Gu Y-Z, 40:519–61
Guengerich FP, 39:1–17
Guyton KZ, 41:421–42

Halmes NC, 37:91–117
Hammond HK, 39:343–60
Hanoune J, 41:145–74
Harris RA, 41:23–51
Hefti F, 37:239–67
Heinrich M, 38:539–65
Hickson ID, 41:367–401
Hobbs AJ, 39:191–220
Hockerman GH, 37:361–96
Hoffman AR, 38:45–61
Hogenesch JB, 40:519–61
Holford NHG, 40:209–34; 41:625–59
Holm-Waters S, 41:237–60
Hook SS, 41:471–505
Hosokawa M, 38:257–88
Houghten RA, 40:273–82
Hrycyna CA, 39:361–97

Insel PA, 39:175–89, 343–60; 41:593–624
Ishii I, 41:507–34
Ito K, 38:461–99

Iwatsubo T, 38:461–99

Joad JP, 37:29–52
Johnson BD, 37:361–96
Johnson DG, 39:295–312

Kanamitsu S, 38:461–99
Kastrissios H, 37:451–75
Kedzierski RM, 41:851–76
Kensler TW, 41:421–42
Kim RB, 41:815–50
Kimelberg HK, 39:151–73
Kimko HC, 40:209–34
Kitteringham NR, 41:443–70
Klaassen CD, 39:267–94
Klein PS, 41:789–813
Kobilka BK, 38:351–73
Kramer RE, 39:127–50
Krupnick JG, 38:289–319

Lau SS, 38:229–55
Law P-Y, 40:389–430
Lebedeva I, 41:403–19
Lee HC, 41:317–45
Lee SJ, 41:569–91
Lefer DJ, 40:283–94
Lemasters JJ, 37:327–38
Le Novère N, 40:431–58
Lesko LJ, 41:347–66
Li T-K, 41:53–77
Li X, 39:53–65
Lin JH, 41:535–67
Linden J, 41:775–87
Lipton SA, 38:159–77
Liu J, 39:267–94
Liu LF, 41:53–77
Loh HH, 40:389–430
LoPachin RM, 39:151–73
Lu AYH, 41:535–67

Maines MD, 37:517–54
Mao GE, 39:399–430
Marcus R, 38:45–61
Marrone TJ, 37:71–90
Martin E, 41:203–36
Masters SC, 40:619–49
McCammon JA, 37:71–90
McEwen BS, 41:569–91
McLeod HL, 41:101–21
Means AR, 41:471–505
Melchert RB, 38:63–96
Melvin WT, 41:297–316
Metcalf B, 40:193–208
Meyer UA, 37:269–96
Miller RJ, 38:201–27
Moncada S, 39:191–220
Monks TJ, 38:229–55
Monteleone JPR, 40:209–34
Montfort WR, 41:261–95
Murad F, 41:203–36
Murray GI, 41:297–316
Myers SA, 41:661–90
Myers SJ, 39:221–41

Nagata K, 40:159–76
Nakajima Y, 38:461–99
Nathan L, 37:477–515
Neer EJ, 37:167–203
Negishi M, 41:123–43
Nemeroff CB, 41:877–906
Nilsson M, 41:237–60
Norbury CJ, 41:367–401
North RA, 40:563–80

Ohlstein EH, 40:177–91
Oliff A, 37:143–66
O'Neill PM, 41:443–70
Ortiz de Montellano BR, 38:539–65
Otterness DM, 39:19–52
Owens MJ, 41:877–906
Ozawa CR, 40:295–317

Park BK, 41:443–70
Pastan I, 39:361–97
Peck CC, 40:209–34
Peterson BZ, 37:361–96
Phiel CJ, 41:789–813
Pin J-P, 37:205–37
Pinkerton KE, 37:29–52
Plaa GL, 40:43–65
Posner GH, 41:421–42
Post SR, 39:343–60
Powis G, 41:261–95
Pratt WB, 37:297–326
Puga A, 39:67–101
Pumford NR, 37:91–117

Ramachandra M, 39:361–97
Ramos KS, 39:243–65
Rana BK, 41:593–624
Rittling SR, 41:723–49
Robles M, 38:539–65
Rodan GA, 38:375–88
Rodriguez E, 38:539–65
Rodriguez RJ, 38:63–96
Rohrer DK, 38:351–73
Ruffolo RR Jr, 40:177–91

Safe SH, 38:121–58
Sagi SA, 40:459–89
Sah VP, 40:459–89
Satoh T, 38:257–88
Seal RP, 39:431–56
Seasholtz TM, 40:459–89
Sheiner L, 40:67–96
Shertzer HG, 39:67–101
Shiina T, 41:593–624
Shoham M, 41:175–202
Sibley DR, 39:313–41
Snyder SH, 39:53–65
Springer ML, 40:295–317
Starkov AA, 40:353–88
Stauber A, 40:491–518
Steimer J-L, 40:67–96
Stein CA, 41:403–19
Stein CM, 41:815–50
Steinberg SF, 41:751–73
Stout SC, 41:877–906
Strassburg CP, 40:581–618
Streit WJ, 39:151–73
Strosberg AD, 37:421–50
Stuehr DJ, 37:339–59
Subramanian RR, 40:619–49
Sueyoshi T, 41:123–43
Sugiyama Y, 38:461–99
Surprenant A, 40:563–80
Szumlanski CL, 39:19–52

Tedroff J, 41:237–60
Thibonnier A, 41:175–202

Thibonnier M, 41:175–202
Thummel KE, 38:389–430
Thurman RG, 37:327–38
Trudell JR, 41:23–51
Tukey RH, 40:581–618
Turko IV, 41:203–36

Ulrich RG, 40:335–52

Vane JR, 38:97–120
Venter JC, 40:97–132

Walker CL, 39:295–312
Wallace KB, 40:353–88
Waring JF, 40:335–52
Waters N, 41:237–60
Wei L-N, 37:119–41
Weiner JA, 41:507–34
Weinshilboum RM, 39:19–52
West JE, 38:539–65
White RE, 40:133–57
Whitlock JP Jr, 39:103–25
Wilkinson GR, 38:389–430
Witschi H, 37:29–52
Wong YH, 40:389–430
Wood AJJ, 41:815–50

Xie H-G, 41:815–50

Yamakura T, 41:23–51
Yamazoe Y, 40:159–76
Yanagisawa M, 41:851–76
Yoshimura N, 41:691–721

Zanger UM, 37:269–96
Zhang L, 38:431–60
Zheng B, 40:235–71
Zimmerman BG, 37:53–69

CHAPTER TITLES, VOLUMES 37–41

Prefatory

Pharmacology

A Rewarding Research Pathway	A Goldstein	37:1–28
A Quest for Erythropoietin Over Nine Decades	JW Fisher	38:1–20
Targets of Drug Action	A Burgen	40:1–16
High-Throughput Screening in Drug Metabolism and Pharmacokinetic Support of Drug Discovery	RE White	40:133–57

Toxicology

Laboratory of Chemical Pharmacology, National Heart, Lung, and Blood Institute, NIH: A Short History	JR Gillette	40:19–41
Chlorinated Methanes and Liver Injury: Highlights of the Past 50 Years	GL Plaa	40:43–65
Central Role of Peroxisome Proliferator-Activated Receptors in the Actions of Peroxisome Proliferators	JC Corton, SP Anderson, A Stauber	40:491–518
Toxicology Comes of Age	J Doull	41:1–21

General Topics in Pharmacology and Toxicology

Receptors

Pharmacology and Functions of Metabotropic Glutamate Receptors	PJ Conn, J-P Pin	37:205–37
The Role of the hsp90-Based Chaperone System in Signal Transduction by Nuclear Receptors and Receptors Signaling via Map Kinase	WB Pratt	37:297–326
Structure and Function of the β_3-Adrenergic Receptor	AD Strosberg	37:421–50
Cannabinoid Receptors and Their Endogenous Agonists	CC Felder, M Glass	38:179–200
Presynaptic Receptors	RJ Miller	38:201–27
From GABAA Receptor Diversity Emerges A Unified Vision of GABAergic Inhibition	E Costa	38:321–50
Insights from In Vivo Modification of Adrenergic Receptor Gene Expression	DK Rohrer, BK Kobilka	38:351–73

Genetic Regulation of Glutamate Receptor Ion Channels	SJ Myers, R Dingledine, K Borges	39:221–41
New Insights into Dopaminergic Receptor Function Using Antisense and Genetically Altered Animals	DR Sibley	39:313–41
5-HT_6 Receptors as Emerging Targets for Drug Discovery	TA Branchek, TP Blackburn	40:319–34
Nicotinic Receptors at the Amino Acid Level	P-J Corringer, N Le Novère, J-P Changeux	40:431–58
Pharmacology of Clonded P2X Receptors	RA North, A Surprenant	40:563–80
Lysophospholipid Receptors	N Fukushima, I Ishii, JJ Contos, JA Weiner, J Chun	41:507–34
Genetic Variations and Polymorphisms of G Protein-Coupled Receptors: Functional and Therapeutic Implications	BK Rana, T Shiina, PA Insel	41:593–624
Prostanoid Receptors: Subtypes and Signaling	RM Breyer, CK Bagdassarian, SA Myers, MD Breyer	41:661–90
Role of Osteopontin in Cellular Signaling and Toxicant Injury	DT Denhardt, CM Giachelli, SR Rittling	41:723–49
Molecular Approach to Adenosine Receptors: Receptor-Mediated Mechanisms of Tissue Protection	J Linden	41:775–87
Renal System		
Pharmacology of the Lower Urinary Tract	WC de Groat, N Yoshimura	41:691–721
Signal Transduction		
Physiological Functions of Cyclic ADP-Ribose and NAADP as Calcium Messengers	HC Lee	41:317–45
Synaptic Functions		
Molecular Determinants of Drug Binding and Action on L-Type Calcium Channels	GH Hockerman, BZ Peterson, BD Johnson, WA Catterall	37:361–96
Signal Transduction in Environmental Neurotoxicity	LG Costa	38:21–43

Inhibition of Nitric Oxide Synthase as a Potential Therapeutic Target	AJ Hobbs, A Higgs, S Moncada	39:191–220
Redox Regulation of *c-Ha-ras* and Osteopontin Signaling in Vascular Smooth Muscle Cells: Implications in Chemical Atherogenesis	KS Ramos	39:243–65
Cyclins and Cell Cycle Checkpoints	DG Johnson, CL Walker	39:295–312
The Regulator of G Protein Signaling Family	L De Vries, B Zheng, T Fischer, E Elenko, MG Farquhar	40:235–71
Pharmacology of Selectin Inhibitors in Ischemia/Reperfusion States	DJ Lefer	40:283–94
The Role of Rho in G Protein Coupled Receptor Signal Transduction	VP Sah, TM Seasholtz, SA Sagi, JH Brown	40:459–89
14-3-3 Proteins: Structure, Function, and Regulations	H Fu, RR Subramanian, SC Masters	40:619–49
Transporters		
Compartmentation of G Protein-Coupled Signaling Pathways in Cardiac Myocytes	SF Steinberg, LL Brunton LL	41:751–73
Enzymes		
The Heme Oxygenase System: A Regulator of Second-Messenger Gases	MD Maines	37:517–54
The Mammalian Carboxylesterases: From Molecules to Functions	T Satoh, M Hosokawa	38:257–88
The Role of Receptor Kinases and Arrestins in G Protein-Coupled Receptor Regulation	JG Krupnick, JL Benovic	38:289–319
Methylation Pharmacogenetics: Catechol O-Methyltransferase, Thiopurine Methyltransferase, and Histamine N-Methyltransferase	RM Weinshilboum, DM Otterness, CL Szumlanski	39:19–52
Regulation and Inhibition of Phospholipase A_2	J Balsinde, MA Balboa, PA Insel, EA Dennis	39:175–89
Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease	RH Tukey, CP Strassburg	40:581–618

Tumor Cell Death Induced by Topoisomerase-Targeting Drugs	T-K Li, LF Liu	41:53–77
Phenobarbital Response Elements of Cytochrome P450 Genes and Nuclear Receptors	T Sueyoshi, M Negishi	41:123–43
Regulation and Role of Adenylyl Cyclase Isoforms	J Hanoune, N Defer	41:145–74

Chemical Agents

Protein Targets of Xenobiotic Reactive Intermediates	NR Pumford, NC Halmes	37:91–117
G Protein Beta-Gamma Subunits	DE Clapham, EJ Neer	37:167–203
Pharmacology of Neurotrophic Factors	F Hefti	37:239–67
Structure-Function Aspects in the Nitric Oxide Synthases	DJ Stuehr	37:339–59
Enzymatic Methylation of Arsenic Species and Other New Approaches to Arsenic Toxicity	HV Aposhian	37:397–419
The Pharmacology and Toxicology of Polyphenolic-Glutathione Conjugates	TJ Monks, SS Lau	38:229–55
Ethnopharmacology of Mexican Asteraceae (Compositae)	M Heinrich, M Robles, JE West, BR Ortiz de Montellano, E Rodriguez	38:539–65
The Pineal Gland and Melatonin: Molecular and Pharmacologic Regulation	J Borjigin, X Li, SH Snyder	39:53–65
Regulation of Gene Expression by Reactive Oxygen	TP Dalton, HG Shertzer, A Puga	39:67–101
Cytotoxicity of Short-Chain Alcohols	RC Baker, RE Kramer	39:127–50
Metallothionein: An Intracellular Protein to Protect Against Cadmium Toxicity	CD Klaassen, J Liu, S Choudhuri	39:267–94
Teratology of Retinoids	MD Collins, GE Mao	39:399–430
The Clinical Pharmacology of L-Arginine	RH Böger, SM Bode-Böger	41:79–99
The Basic and Clinical Pharmacology of Nonpeptide Vasopressin Receptor Antagonists	M Thibonnier, P Coles, A Thibonnier, M Shoham	41:175–202
Novel Effects of Nitric Oxide	KL Davis, E Martin, IV Turko, F Murad	41:203–36

Biotransformation

Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism	UA Meyer, UM Zanger	37:269–96
In Vitro and In Vivo Drug Interactions Involving Human CYP3A	KE Thummel, GR Wilkinson	38:389–430
Glutathione-Dependent Bioactivation of Haloalkenes	MW Anders, W Dekant	38:501–37
Cytochrome P-450 3A4: Regulation and Role in Drug Metabolism	FP Guengerich	39:1–17
Induction of Cytochrome P4501A1	JP Whitlock Jr	39:103–25
Metabolism of Fluorine-Containing Drugs	BK Park, NR Kitteringham, PM O'Neill	41:443–70
Interindividual Variability in Inhibition and Induction of Cytochrome P450 Enzymes	JH Lin, AYH Lu	41:535–67

Nucleic Acids

Cellular Responses to DNA Damage	CJ Norbury, ID Hickson	41:367–401
Ca^{2+}/CaM-Dependent Kinases: From Activation to Function	SS Hook, AR Means	41:471–505

Pharmacokinetics/Toxicokinetics

Role of Organic Cation Transporters in Drug Absorption and Elimination	L Zhang, CM Brett, KM Giacomini	38:431–60
Biochemical, Cellular, and Pharmacological Aspects of the Multidrug Transporter	SV Ambudkar, S Dey, CA Hrycyna, M Ramachandra, I Pastan, MM Gottesman	39:361–97
Mitochondrial Targets of Drug Toxicity	KB Wallace, AA Starkov	40:353–88

Cancer and Carcinogenesis

The Potential of Farnesyltransferase Inhibitors as Cancer Chemotherapeutics	JB Gibbs, A Oliff	37:143–66
Interactions Between Hormones and Chemicals in Breast Cancer	SH Safe	38:121–58
Properties and Biological Activities of Thioredoxins	G Powis, WR Montfort	41:261–95
Cancer Chemoprevention Using Natural Vitamin D and Synthetic Analogs	KZ Guyton, TW Kensler, GH Posner	41:421–42

Clinical Therapeutics

Medication Compliance as a Feature in Drug Development	H Kastrissios, TF Blaschke	37:451–75
Dual Protease Inhibitor Therapy in HIV-Infected Patients: Pharmacologic Rationale and Clinical Benefits	C Flexner	40:651–76
Pharmacogenomics: Unlocking the Human Genome for Better Drug Therapy	HL McLeod, WE Evans	41:101–21
Antisense Oligonucleotides: Promise and Reality	I Lebedeva, CA Stein	41:403–19

Drug Development Science

Structure-Based Drug Design: Computational Advances	TJ Marrone, JM Briggs, JA McCammon	37:71–90
Parallel Array and Mixture-Based Synthetic Combinatorial Chemistry: Tools for the Next Millennium	RA Houghten	40:273–82
A Novel Means of Drug Delivery: Myoblast-Mediated Gene Therapy and Regulatable Retroviral Vectors	CR Ozawa, ML Springer, HM Blau	40:295–317
Use of Biomarkers and Surrogate Endpoints in Drug Development and Regulatory Decision Making: Criteria, Validation, Strategies	L Lesko, AJ Atkinson Jr.	41:347–66

Systems

Immune System/Inflammation

Cyclooxygenases 1 and 2	JR Vane, YS Bakhle, RM Botting	38:97–120

Central Nervous System

Glial Cells in Neurotoxicity Development	M Aschner, JW Allen, HK Kimelberg, RM LoPachin, WJ Streit	39:151–73
Excitatory Amino Acid Transporters: A Family in Flux	RP Seal, SG Amara	39:431–56
Molecular Mechanisms and Regulation of Opiod Receptor Signaling	P-Y Law, YH Wong, HH Loh	40:389–430

Anesthetics and Ion Channels: Molecular Models and Sites of Action	T Yamakura, E Bertaccini, JR Trudell, RA Harris	41:23–51
Interactions Between Monoamines, Glutamate, and GABA in Schizophrenia: New Evidence	A Carlsson, N Waters, S Holm-Waters, J Tedroff, M Nilsson, ML Carlsson	41:237–60
Drug Treatment Effects on Disease Progression	P Chan, N Holford	41:625–59
Molecular Targets of Lithium Action	CJ Phiel, PS Klein	41:789–813
Neurokinin1 Receptor Antagonists as Potential Antidepressants	SC Stout, MJ Owens, CB Nemeroff	41:877–906
Autonomic Nervous System		
β-Adrenergic Receptors and Receptor Signaling in Heart Failure	SR Post, HK Hammond, PA Insel	39:343–60
Genetic Variations and Polymorphisms of G Protein-Coupled Receptors: Functional and Therapeutic Implications	BK Rana, T Shiina, PA Insel	41:593–624
Cardiovascular System		
Tissue Renin-Angiotensin Systems: A Site of Drug Action?	BG Zimmerman, EW Dunham	37:53–69
Reperfusion Injury After Liver Preservation for Transplantation	JJ Lemasters, RG Thurman	37:327–38
Endothelin System: The Double-Edged Sword in Health and Disease	RM Kedzierski, M Yanagisawa	41:851–76
Endocrine System		
Estrogens and Atherosclerosis	L Nathan, G Chaudhuri	37:477–515
Growth Hormone As Therapy for Older Men and Women	R Marcus, AR Hoffman	38:45–61
Mechanism of Action of Biophosphates	GA Rodan	38:375–88
Neurotrophic and Neuroprotective Actions of Estrogens and Their Therapeutic Implications	SJ Lee, BS McEwen	41:569–91

Pulmonary System

The Toxicology of Environmental Tobacco Smoke — H Witschi, JP Joad, KE Pinkerton — 37:29–52

Microbial Systems

Neuronal Injury Associated with HIV-1: Approaches to Treatment — SA Lipton — 38:159–77

Miscellaneous

Techniques

Transgenic Animals as New Approaches in Pharmacological Studies — L-N Wei — 37:119–41

Predictive Value of In Vitro Model Systems in Toxicology — JC Davila, RJ Rodriguez, RB Melchert, D Acosta Jr — 38:63–96

Quantitative Prediction of In Vivo Drug Clearance and Drug Interactions from In Vitro Data on Metabolism, and Together with Binding and Transport — K Ito, T Iwatsubo, S Kanamitsu, Y Nakajima, Y Sugiyama — 38:461–99

The Impact of Genomics-Based Technologies on Drug Safety Evaluation — JF Waring, RG Ulrich — 40:335–52

Environmental Toxicity

The PAS Superfamily: Sensors of Environmental and Developmental Signals — Y-Z Gu, JB Hogenesch, CA Bradfield — 40:519–61

Pharmacology and Toxicology in the New Millennium

Pharmacokinetic/Pharmacodynamic Modeling in Drug Development — LB Sheiner, J-L Steimer — 40:67–96

Sequencing the Entire Genomes of Free-Living Organisms: The Foundation of Pharmacology in the New Millenium — S Broder, JC Venter — 40:97–132

High-Throughput Screening in Drug Metabolism and Pharmacokinetic Support of Drug Discovery — RE White — 40:133–57

Pharmacogenetics of Sulfotransferase — K Nagata, Y Yamazoe — 40:159–76

Drug Discovery in the Next Millennium	EH Ohlstein, RR Ruffolo Jr, JD Elliott	40:177–91
The Impact of Genomics on Drug Discovery	C Debouck, B Metcalf	40:193–208
Simulation of Clinical Trials	NHG Holford, HC Kimko, JPR Monteleone, CC Peck	40:209–34